Interestingly, female patients displayed no statistical survival difference between the high and low MARCHF9 expression subgroups, suggesting that MARCHF9 may not significantly affect the overall survival of female COAD patients (Figure 3(a), P=0.35). This evidence concerns the gene MARCHF9 and colon adenocarcinoma.